Inspire Medical faces class‑action after “Inspire V” launch failure — stock dives 32%

A major lawsuit has been filed against Inspire Medical Systems, Inc. (ticker: INSP) after its rollout of the next‑generation sleep‑apnea device Inspire V reportedly failed — and investors are being urged to step forward. On December 3, 2025, shareholder‑rights law firm Hagens Berman Sobol Shapiro LLP announced that the deadline to seek appointment as lead plaintiff in the class‑action is January 5, 2026. The lawsuit claims the company misled investors by assuring that Inspire V was “operationally ready” for launch, while allegedly concealing critical failures in billing software and training that made the rollout impossible. According to the complaint, the problems became evident when software updates needed for Medicare claims processing did not take effect until July 1, 2025 — meaning centers could not bill for procedures using Inspire V. Meanwhile, many customers reportedly still held large inventories of the older Inspire IV device, limiting demand for the new model. As a result of these failures, Inspire slashed its 2025 EPS guidance by over 80%. The subsequent stock drop — a plunge of about 32%, translating to a $42.04 per‑share loss — followed the company’s admission of an “elongated timeframe” for the Inspire V launch. Hagens Berman argues that investors who bought INSP shares between August 6, 2024 and August 4, 2025 and suffered losses may be entitled to damages. The firm is also investigating whether the company intentionally concealed inventory surpluses of Inspire IV to maintain an inflated stock price. && #InspireMedical #InspireV #InvestorAlert #ClassAction && #InspireMedical #InspireV #InvestorAlert #ClassAction #SlimScan #GrowthStocks #CANSLIM